business
Cancer Drugmaker Parabilis Seeks $475 Million in US IPO
Parabilis Medicines, a clinical-stage cancer drug developer, is seeking to raise $475 million in an initial public offering.
Read full story on Bloomberg Markets → More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop